Profile data is unavailable for this security.
About the company
Acadia Pharmaceuticals Inc. is a biopharmaceutical company. It develops and commercializes medicines that address unmet medical needs in central nervous system (CNS) disorders and rare diseases. It has a portfolio of product candidates and research programs that are designed to address significant unmet medical needs in CNS disorders and rare diseases. Its pipeline includes NUPLAZID (pimavanserin), DAYBUE (trofinetide), ACP-101, ACP-204, and ACP-711. NUPLAZID is a selective serotonin inverse agonist/antagonist preferentially targeting the 5-HT2A receptor. NUPLAZID is developed for the treatment for Parkinson's Disease Psychosis. Trofinetide is a novel synthetic analog of the amino-terminal tripeptide of insulin-like growth factor 1 designed to treat the core symptoms of Rett syndrome by reducing neuroinflammation and supporting synaptic function. Its early-stage research programs and product candidates include ACP-211, ACP-2591, ACP-271, and Antisense Oligonucleotide (ASO) Programs.
- Revenue in USD (TTM)1.05bn
- Net income in USD261.17m
- Incorporated1997
- Employees653.00
- LocationACADIA Pharmaceuticals Inc12830 El Camino Real, Suite 400SAN DIEGO 92130United StatesUSA
- Phone+1 (858) 558-2871
- Fax+1 (858) 558-2872
- Websitehttps://acadia.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Edgewise Therapeutics Inc | 0.00 | -157.24m | 3.18bn | 136.00 | -- | 5.68 | -- | -- | -1.58 | -1.58 | 0.00 | 5.28 | 0.00 | -- | -- | 0.00 | -28.73 | -26.21 | -29.83 | -27.42 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -33.60 | -- | 48.78 | -- |
| Xenon Pharmaceuticals Inc | 7.50m | -306.33m | 3.21bn | 316.00 | -- | 5.72 | -- | 427.38 | -3.88 | -3.88 | 0.0952 | 7.26 | 0.0104 | -- | 8.57 | 23,734.18 | -42.44 | -22.00 | -44.53 | -22.93 | -- | -- | -4,084.45 | -1,082.36 | -- | -- | 0.00 | -- | -- | -- | -28.48 | -- | 19.92 | -- |
| Legend Biotech Corp (ADR) | 908.96m | -239.70m | 3.25bn | 2.90k | -- | 3.21 | -- | 3.57 | -1.30 | -1.30 | 4.94 | 5.48 | 0.5271 | 13.60 | 936.59 | 349,601.20 | -13.90 | -30.18 | -17.47 | -36.54 | 60.55 | -- | -26.37 | -154.41 | 2.80 | -1.36 | 0.2886 | -- | 119.97 | 59.91 | 65.84 | -- | -18.48 | -- |
| Alumis Inc | 22.12m | -245.15m | 3.31bn | 233.00 | -- | 7.20 | -- | 149.56 | -3.85 | -3.85 | 0.3057 | 3.69 | 0.0491 | -- | 9.28 | 131,672.60 | -54.44 | -- | -61.16 | -- | -- | -- | -1,108.24 | -- | -- | -- | 0.00 | -- | -- | -- | -89.84 | -- | -- | -- |
| Viking Therapeutics Inc | 0.00 | -359.64m | 3.35bn | 53.00 | -- | 5.21 | -- | -- | -3.18 | -3.18 | 0.00 | 5.57 | 0.00 | -- | -- | 0.00 | -44.29 | -31.71 | -47.32 | -33.62 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -227.05 | -- | -- | -- |
| Erasca Inc | 0.00 | -127.69m | 3.72bn | 103.00 | -- | 9.79 | -- | -- | -0.4506 | -0.4506 | 0.00 | 1.23 | 0.00 | -- | -- | 0.00 | -26.90 | -41.53 | -28.68 | -44.78 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -29.28 | -- | -36.84 | -- |
| ACADIA Pharmaceuticals Inc | 1.05bn | 261.17m | 3.73bn | 653.00 | 14.19 | 4.06 | 13.54 | 3.56 | 1.55 | 1.55 | 6.21 | 5.42 | 0.9075 | 1.88 | 9.78 | 1,603,550.00 | 22.64 | -13.15 | 32.50 | -16.74 | 91.92 | 94.49 | 24.94 | -16.00 | 2.94 | -- | 0.00 | -- | 31.85 | 23.08 | 469.50 | -- | -14.26 | -- |
| Grail Inc | 141.83m | -406.24m | 3.80bn | 1.00k | -- | 1.57 | -- | 26.80 | -11.63 | -11.63 | 4.06 | 61.94 | 0.0496 | -- | 9.01 | 141,827.00 | -14.21 | -49.71 | -14.65 | -50.85 | 46.88 | 39.69 | -286.43 | -3,510.18 | -- | -- | 0.00 | -- | 34.90 | -- | -38.30 | -- | 9.34 | -- |
| Arcellx Inc | 35.90m | -217.90m | 3.96bn | 163.00 | -- | 8.98 | -- | 110.34 | -3.92 | -3.92 | 0.6462 | 7.63 | 0.0505 | -- | 9.57 | 220,233.10 | -30.67 | -27.24 | -37.39 | -32.13 | -- | -- | -607.01 | -212.50 | -- | -- | 0.00 | -- | -2.16 | -- | -51.86 | -- | 28.52 | -- |
| Terns Pharmaceuticals Inc | 0.00 | -94.44m | 4.01bn | 59.00 | -- | 11.64 | -- | -- | -1.03 | -1.03 | 0.00 | 3.25 | 0.00 | -- | -- | 0.00 | -27.78 | -32.69 | -28.92 | -35.03 | -- | -- | -- | -33,013.70 | -- | -- | 0.00 | -- | -- | -- | 1.50 | -- | -45.82 | -- |
| Crinetics Pharmaceuticals Inc | 1.54m | -423.10m | 4.05bn | 437.00 | -- | 3.77 | -- | 2,639.66 | -4.53 | -4.53 | 0.0165 | 11.34 | 0.0014 | -- | 0.2622 | 3,512.59 | -39.66 | -36.96 | -42.19 | -39.20 | -- | -- | -27,563.32 | -7,785.98 | -- | -- | 0.00 | -- | -74.11 | -2.73 | -39.10 | -- | 50.86 | -- |
| BillionToOne Inc | -100.00bn | -100.00bn | 4.06bn | -- | -- | -- | -- | -- | -- | -- | -- | 4.02 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | 5.75 | -- | 0.238 | -- | 112.72 | -- | 49.72 | -- | -- | -- |
| CG Oncology Inc | 2.17m | -151.48m | 4.15bn | 113.00 | -- | 5.86 | -- | 1,910.91 | -2.03 | -2.03 | 0.0292 | 8.78 | 0.0034 | -- | 6.67 | 19,238.94 | -23.63 | -- | -24.51 | -- | 4.09 | -- | -6,967.99 | -- | 22.74 | -- | 0.0043 | -- | 458.33 | -- | -29.85 | -- | -- | -- |
| Gyroscope Therapeutics Holdings Ltd(ADR) | -100.00bn | -100.00bn | 4.25bn | 167.00 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -70.87 | -- | -58.56 | -- | -- | -- |
Data as of Feb 13 2026. Currency figures normalised to ACADIA Pharmaceuticals Inc's reporting currency: US Dollar USD
61.38%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Baker Bros. Advisors LPas of 30 Sep 2025 | 42.90m | 25.36% |
| BlackRock Fund Advisorsas of 31 Dec 2025 | 18.44m | 10.90% |
| The Vanguard Group, Inc.as of 31 Dec 2025 | 14.11m | 8.34% |
| SSgA Funds Management, Inc.as of 31 Dec 2025 | 7.91m | 4.68% |
| RTW Investments LPas of 30 Sep 2025 | 7.14m | 4.22% |
| Geode Capital Management LLCas of 31 Dec 2025 | 3.24m | 1.92% |
| Dimensional Fund Advisors LPas of 31 Dec 2025 | 2.77m | 1.64% |
| Adage Capital Management LPas of 30 Sep 2025 | 2.48m | 1.47% |
| Palo Alto Investors LPas of 30 Sep 2025 | 2.47m | 1.46% |
| Braidwell LPas of 30 Sep 2025 | 2.38m | 1.41% |
More ▼
Data from 30 Sep 2025 - 31 Dec 2025Source: FactSet Research Systems Inc.
